# Ebola: The Scientific Hurdles Behind the Lack of Vaccines Despite decades of knowledge, the Bundibugyo Ebola variant remains without a licensed vaccine. - **Source:** [DW – Africa](https://www.dw.com/en) - **Published:** 2026-11-07 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/4b40be1c-66ff-40a7-bf7b-a7a2019b0a89 ## Persistent Outbreak Challenges The Democratic Republic of Congo is currently battling a major outbreak of the Bundibugyo Ebola virus. Although this pathogen was first identified in 2007, no licensed vaccine or official treatment exists for this specific strain. Experts argue that previous outbreaks in 2007 and 2012 represented missed opportunities for proactive vaccine development. ## Scientific Vaccine Potential Unlike influenza, which mutates rapidly, or HIV, which evades immune defenses, the Ebola virus is considered a predictable vaccine candidate. Researchers believe developing a vaccine for the Bundibugyo variant is straightforward from an immunological perspective. However, the lack of precautionary funding often shifts research focus toward other more prioritized pathogens. ## The Variant Specificity Problem Ebola is not a single virus but a genus containing distinct types like Zaire, Sudan, and Bundibugyo. The existing vaccine, Ervebo, is only licensed for the Zaire variant. Because of this specificity, the current vaccine provides limited protection against the Bundibugyo strain, leaving populations vulnerable despite having access to other Ebola vaccines. ## Cross-Reactive Immune Responses A recent study by the German Center for Infection Research investigated whether Ervebo could trigger immune responses against other Ebola types. Researchers identified cross-reactive T-cell responses against the Bundibugyo virus. While promising, it remains unclear if these responses provide actual clinical protection or merely result in a milder disease progression. ## Ethical Vaccination Dilemmas Deploying an unproven vaccine during an active outbreak presents significant ethical risks. Experts warn that mass vaccination without proof of efficacy could create a false sense of security. Furthermore, if the vaccine fails to protect, it might erode public trust, potentially causing communities to refuse future, more effective medical interventions. ## Logistical and Conflict Barriers Medical innovation alone cannot contain Ebola. In the Democratic Republic of Congo, ongoing conflicts, difficult transport routes, and attacks on healthcare facilities severely hinder containment efforts. Even with improved diagnostic tools, the practical challenge remains moving samples over long distances, which delays the speed of the overall public health response. ## New Clinical Trial Initiatives The Tumaini study has launched in the DRC to test multiple vaccine candidates, including Ervebo and a Moderna mRNA vaccine. This study aims to provide the first reliable data regarding efficacy against the Bundibugyo virus. However, experts estimate that widespread availability of a successful vaccine may not occur until mid-2027. ## Future Pan-Ebola Strategies The long-term goal for researchers is the development of cross-reactive pan-Ebola vaccines that protect against all known variants. While current efforts focus on the immediate Bundibugyo threat, scientists are prioritizing these broader solutions. The ultimate challenge remains balancing rapid response needs with the rigorous scientific validation required for global public health. ## Sources covering this story - https://www.dw.com/en/ebola-why-is-there-still-no-vaccine/a-79888134?maca=en-rss-en-africa-8291-rdf — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._